Was PTC Therapeutics playing games when it tried to defuse the deflazacort controversy with a $35,000 annual price?
When PTC Therapeutics $PTCT CEO Stuart Peltz rolled out the biotech’s Q1 report this morning, he noted that company execs came up with what they believe is a “sustainable” price for the cheap, old steroid acquired from the controversial crew at Marathon Pharmaceuticals for $140 million up front and targeted at the Duchenne community in the US.
The net price, he said, would average $35,000 a year for a patient that weighed 25 kilograms, or 55 pounds.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.